Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis

Pharmacotherapy

Volumn 23, Issue 5, 2003, Pages 690-694

  Barnett, Arnold I ^a   Crémieux, Pierre Y ^b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b ANALYSIS GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ARTIFACT; CHRONIC KIDNEY DISEASE; CONFIDENCE INTERVAL; DOSE CALCULATION; DRUG MEGADOSE; DRUG STABILITY; EXPERIMENTAL MODEL; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; NONLINEAR SYSTEM; REVIEW; STATISTICAL SIGNIFICANCE;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; ERYTHROPOIETIN; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; THERAPEUTIC EQUIVALENCY;

EID: 0037967394     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.5.690.32195     Document Type: Review

References (2)

1. Scott SD. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies. Pharmacotherapy 2002;22(9 pt 2):160S-5.
2. Center for Biologics Evaluation and Research. Medical officer clinical review of BLA99-1492/STN103951, Amgen Inc. Darbepoetin alfa (ARANESP™) for the treatment of anemia associated with chronic renal failure, 2001.